Overview: PDGFRA/PDGFRB/FGFR1/CBFB Rearrangements TestIntroduction: The PDGFRA/PDGFRB/FGFR1/CBFB Rearrangements Test tests for gene rearrangements to diagnose leukemias or myeloproliferative disorders, helping guide targeted therapy for abnormal blood counts. Affecting 1 in 100,000 people with leukemia, these rearrangements pose diagnostic challenges due to genetic complexity. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses FISH/PCR for high accuracy, supporting cytogenetics screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Gene Rearrangement Test, Myeloid Disorder Assay.
FDA Status: Laboratory-developed test (LDT), meeting cytogenetics standards for diagnostic reliability.
Historical Milestone: Gene rearrangement testing began in the 1990s with research by Golub, who identified these genes. FISH/PCR advancements by Abbott Molecular improved detection, surpassing earlier karyotyping.
Purpose: Detects gene rearrangement status to diagnose leukemias or myeloproliferative disorders, guides tyrosine kinase inhibitors, and evaluates patients with fatigue, aiming to manage disease.
Test Parameters: Gene rearrangement status
Pretest Condition: Bone marrow biopsy required. Collect whole blood or bone marrow. Report history of blood disorders.
Specimen: Whole Blood (EDTA, 3-5 mL), Bone Marrow (EDTA, 1-3 mL); Bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fatigue or abnormal blood counts. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., leukemia progression), and sample collection risks.
Procedural Considerations: Uses FISH/PCR to detect rearrangements, requiring labs with fluorescence microscopes or thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive rearrangements confirm diagnosis, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal results may require other tests.
Specialist Consultation: Consult a hematologist or oncologist for interpretation.
Additional Supporting Tests: Bone marrow biopsy, CBC, or cytogenetic panel to confirm diagnosis.
Test Limitations: Specific to targeted genes; correlation with clinical status needed. False negatives possible with untested variants.
References: NCCN Guidelines, 2023; Blood, Golub TR, 2022.
